A GENS-based approach to cardiovascular pharmacology: impact on metabolism, pharmacokinetics and pharmacodynamics

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

Bibliography

• 1  Wizeman TM, Pardue MLE. Exploring the Biological Contributions to Human Health: Does Sex Matter? National Academies Press, Washington, DC, USA (2001).
  Google Scholar
• 2  Marino M, Masella R, Bulzomi P, Campesi I, Malorni W, Franconi F. Nutrition and human health from a sex-gender perspective. Mol. Aspects Med.32,1–70 (2011).
  Medline CASGoogle Scholar
• 3  Gandhi M, Aweeka F, Greenblatt RM, Blaschke TF. Sex differences in pharmacokinetics and pharmacodynamics. Annu. Rev. Pharmacol. Toxicol.44,499–523 (2004).▪ Highlights sex-based differences in pharmacologic parameters.
  Medline CASGoogle Scholar
• 4  Franconi F, Brunelleschi S, Steardo L, Cuomo V. Gender differences in drug responses. Pharmacol. Res.55,81–95 (2007).▪ Summarizes gender differences in pharmacology, with a specific focus on drug response.
  Medline CASGoogle Scholar
• 5  Donovan MD. Sex and racial differences in pharmacological response: effect of route of administration and drug delivery system on pharmacokinetics. J. Womens Health (Larchmt)14,30–37 (2005).
  MedlineGoogle Scholar
• 6  Kashuba AD, Nafziger AN. Physiological changes during the menstrual cycle and their effects on the pharmacokinetics and pharmacodynamics of drugs. Clin. Pharmacokinet.34,203–218 (1998).
  Medline CASGoogle Scholar
• 7  Soldin OP, Mattison DR. Sex differences in pharmacokinetics and pharmacodynamics. Clin. Pharmacokinet.48,143–157 (2009).▪ Summarizes the sex-based differences in clinical pharmacology, with a specific focus on pharmacokinetics and pharmacodynamics.
  Medline CASGoogle Scholar
• 8  Schwartz JB. The current state of knowledge on age, sex, and their interactions on clinical pharmacology. Clin. Pharmacol. Ther.82,87–96 (2007).
  Medline CASGoogle Scholar
• 9  Regitz-Zagrosek V. Therapeutic implications of the gender-specific aspects of cardiovascular disease. Nat Rev Drug Discov.5,425–438 (2006).▪ Gender differences in cardiovascular pharmacology, their underlying pathophysiological mechanisms and implications for novel strategies of treatment are discussed.
  Medline CASGoogle Scholar
• 10  Yang Y, Carlin AS, Faustino PJ et al. Participation of women in clinical trials for new drugs approved by the food and drug administration in 2000–2002. J. Womens Health (Larchmt)18,303–310 (2009).
  MedlineGoogle Scholar
• 11  Wenger NK. Coronary heart disease in women: highlights of the past 2 years – stepping stones, milestones and obstructing boulders. Nat. Clin. Pract. Cardiovasc. Med.3,194–202 (2006).
  MedlineGoogle Scholar
• 12  Rogers W. Evidence-based medicine and women: do the principles and practice of EBM further women’s health? Bioethics18,50–71 (2004).
  MedlineGoogle Scholar
• 13  Pirmohamed M, James S, Meakin S et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ329,15–19 (2004).▪▪ Large prospective observational study demonstrating that, among the adverse drug reactions causing admission to hospital, low-dose aspirin, diuretics, warfarin and nonsteroidal anti-inflammatory drugs other than aspirin were most commonly implicated.
  MedlineGoogle Scholar
• 14  Patel H, Bell D, Molokhia M et al. Trends in hospital admissions for adverse drug reactions in England: analysis of national hospital episode statistics 1998–2005. BMC Clin. Pharmacol.7,9 (2007).
  MedlineGoogle Scholar
• 15  Jochmann N, Stangl K, Garbe E, Baumann G, Stangl V. Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseases. Eur. Heart J.26,1585–1595 (2005).
  Medline CASGoogle Scholar
• 16  Pilote L, Dasgupta K, Guru V et al. A comprehensive view of sex-specific issues related to cardiovascular disease. CMAJ176,S1–S44 (2007).▪▪ Both sex and gender differences may account for the worst outcomes in cardiovascular medicine observed in women than in men. However, the interaction between sex-and gender-related factors and cardiovascular outcomes in women still remains unknown.
  MedlineGoogle Scholar
• 17  Franconi F, Carru C, Malorni W, Vella S, Mercuro G. The effect of sex/gender on cardiovascular pharmacology. Curr. Pharm. Des.17,1095–1107 (2011).
  Medline CASGoogle Scholar
• 18  Case AM, Reid RL. Effects of the menstrual cycle on medical disorders. Arch. Intern. Med.158,1405–1412 (1998).
  Medline CASGoogle Scholar
• 19  Khalil RA. Sex hormones, vascular function and the outcome of hormone replacement therapy in cardiovascular disease. Future Cardiol.3,283–300 (2007).
  Medline CASGoogle Scholar
• 20  Olson BR, Forman MR, Lanza E et al. Relation between sodium balance and menstrual cycle symptoms in normal women. Ann. Intern. Med.125,564–567 (1996).
  Medline CASGoogle Scholar
• 21  Van de Werf F, Barron HV, Armstrong PW et al. Incidence and predictors of bleeding events after fibrinolytic therapy with fibrin-specific agents: a comparison of TNK-tPA and rt-PA. Eur. Heart J.22,2253–2261 (2001).
  Medline CASGoogle Scholar
• 22  Mead J. Dysanapsis in normal lungs assessed by the relationship between maximal flow, static recoil, and vital capacity. Am. Rev. Respir. Dis.121,339–342 (1980).
  Medline CASGoogle Scholar
• 23  Rohatagi S, Calic F, Harding N et al. Pharmacokinetics, pharmacodynamics, and safety of inhaled cyclosporin A (ADI628) after single and repeated administration in healthy male and female subjects and asthmatic patients. J. Clin. Pharmacol.40,1211–1226 (2000).
  Medline CASGoogle Scholar
• 24  Berg UB. Differences in decline in GFR with age between males and females. Reference data on clearances of inulin and PAH in potential kidney donors. Nephrol. Dial. Transplant21,2577–2582 (2006).
  Medline CASGoogle Scholar
• 25  Kielstein JT, Bode-Boger SM, Frolich JC, Ritz E, Haller H, Fliser D. Asymmetric dimethylarginine, blood pressure, and renal perfusion in elderly subjects. Circulation107,1891–1895 (2003).
  MedlineGoogle Scholar
• 26  Dias VC, Tendler B, Oparil S, Reilly PA, Snarr P, White WB. Clinical experience with transdermal clonidine in African-American and Hispanic-American patients with hypertension: evaluation from a 12-week prospective, open-label clinical trial in community-based clinics. Am. J. Ther.6,19–24 (1999).
  Medline CASGoogle Scholar
• 27  Roy SD, Flynn GL. Transdermal delivery of narcotic analgesics: pH, anatomical, and subject influences on cutaneous permeability of fentanyl and sufentanil. Pharm. Res.7,842–847 (1990).
  Medline CASGoogle Scholar
• 28  Freire AC, Basit AW, Choudhary R, Piong CW, Merchant HA. Does sex matter? The influence of gender on gastrointestinal physiology and drug delivery. Int. J. Pharm.415,15–28 (2011).
  Medline CASGoogle Scholar
• 29  Soldin OP, Chung SH, Mattison DR. Sex differences in drug disposition. J. Biomed. Biotechnol.2011,187103 (2011).
  MedlineGoogle Scholar
• 30  Klotz U. Pharmacokinetics and drug metabolism in the elderly. Drug Metab. Rev.41,67–76 (2009).
  Medline CASGoogle Scholar
• 31  Hunt CM, Westerkam WR, Stave GM. Effect of age and gender on the activity of human hepatic CYP3A. Biochem. Pharmacol.44,275–283 (1992).
  Medline CASGoogle Scholar
• 32  Zhu B, Liu ZQ, Chen GL et al. The distribution and gender difference of CYP3A activity in Chinese subjects. Br. J. Clin. Pharmacol.55,264–269 (2003).
  Medline CASGoogle Scholar
• 33  Anakk S, Ku CY, Vore M, Strobel HW. Insights into gender bias: rat cytochrome P450 3A9. J. Pharmacol. Exp. Ther.305,703–709 (2003).
  Medline CASGoogle Scholar
• 34  Flockhart DA, Rae JM. Cytochrome P450 3A pharmacogenetics: the road that needs traveled. Pharmacogenomics J.3,3–5 (2003).
  Medline CASGoogle Scholar
• 35  Waxman DJ, Holloway MG. Sex differences in the expression of hepatic drug metabolizing enzymes. Mol. Pharmacol.76,215–228 (2009).
  Medline CASGoogle Scholar
• 36  Bebawy M, Chetty M. Gender differences in p-glycoprotein expression and function: effects on drug disposition and outcome. Curr. Drug Metab.10,322–328 (2009).
  Medline CASGoogle Scholar
• 37  Sakuma T, Kawasaki K, Jarukamjorn K, Nemoto N. Sex differences of drug metabolizing enzymes: female predominant expression of human and mouse cytochrome P450 3A isoforms. J. Health Sci.55,325–337 (2009).
  CASGoogle Scholar
• 38  Tracy TS, Korzekwa KR, Gonzalez FJ, Wainer IW. Cytochrome P450 isoforms involved in metabolism of the enantiomers of verapamil and norverapamil. Br. J. Clin. Pharmacol.47,545–552 (1999).
  Medline CASGoogle Scholar
• 39  Krecic-Shepard ME, Barnas CR, Slimko J, Jones MP, Schwartz JB. Gender-specific effects on verapamil pharmacokinetics and pharmacodynamics in humans. J. Clin. Pharmacol.40,219–230 (2000).
  Medline CASGoogle Scholar
• 40  Schwartz JB, Capili H, Wainer IW. Verapamil stereoisomers during racemic verapamil administration: effects of aging and comparisons to administration of individual stereoisomers. Clin. Pharmacol. Ther.56,368–376 (1994).
  Medline CASGoogle Scholar
• 41  Krecic-Shepard ME, Barnas CR, Slimko J, Schwartz JB. Faster clearance of sustained release verapamil in men versus women: continuing observations on sex-specific differences after oral administration of verapamil. Clin. Pharmacol. Ther.68,286–292 (2000).
  Medline CASGoogle Scholar
• 42  Gupta SK, Atkinson L, Tu T, Longstreth JA. Age and gender related changes in stereoselective pharmacokinetics and pharmacodynamics of verapamil and norverapamil. Br. J. Clin. Pharmacol.40,325–331 (1995).
  Medline CASGoogle Scholar
• 43  Doki K, Homma M, Kuga K et al. Gender-associated differences in pharmacokinetics and anti-arrhythmic effects of flecainide in Japanese patients with supraventricular tachyarrhythmia. Eur. J. Clin. Pharmacol.63,951–957 (2007).
  Medline CASGoogle Scholar
• 44  Meibohm B, Beierle I, Derendorf H. How important are gender differences in pharmacokinetics? Clin. Pharmacokinet.41,329–342 (2002).
  Medline CASGoogle Scholar
• 45  Luzier AB, Killian A, Wilton JH, Wilson MF, Forrest A, Kazierad DJ. Gender-related effects on metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers. Clin. Pharmacol. Ther.66,594–601 (1999).
  Medline CASGoogle Scholar
• 46  Johnson JA, Akers WS, Herring VL, Wolfe MS, Sullivan JM. Gender differences in labetalol kinetics: importance of determining stereoisomer kinetics for racemic drugs. Pharmacotherapy20,622–628 (2000).
  Medline CASGoogle Scholar
• 47  Salazar DE, Much DR, Nichola PS, Seibold JR, Shindler D, Slugg PH. A pharmacokinetic-pharmacodynamic model of d-sotalol Q-Tc prolongation during intravenous administration to healthy subjects. J. Clin. Pharmacol.37,799–809 (1997).
  Medline CASGoogle Scholar
• 48  Melander A, Stenberg P, Liedholm H, Schersten B, Wahlin-Boll E. Food-induced reduction in bioavailability of atenolol. Eur. J. Clin. Pharmacol.16,327–330 (1979).
  Medline CASGoogle Scholar
• 49  Leopold G, Pabst J, Ungethum W, Buhring KU. Basic pharmacokinetics of bisoprolol, a new highly β 1-selective adrenoceptor antagonist. J. Clin. Pharmacol.26,616–621 (1986).
  Medline CASGoogle Scholar
• 50  Thurmann PA, Haack S, Werner U et al. Tolerability of β-blockers metabolized via cytochrome P450 2D6 is sex-dependent. Clin. Pharmacol. Ther.80,551–553 (2006).
  MedlineGoogle Scholar
• 51  Holbrook AM, Pereira JA, Labiris R et al. Systematic overview of warfarin and its drug and food interactions. Arch. Intern. Med.165,1095–1106 (2005).
  Medline CASGoogle Scholar
• 52  Baris N, Kalkan S, Guneri S, Bozdemir V, Guven H. Influence of carvedilol on serum digoxin levels in heart failure: is there any gender difference? Eur. J. Clin. Pharmacol.62,535–538 (2006).
  Medline CASGoogle Scholar
• 53  Shammas FV, Dickstein K. Clinical pharmacokinetics in heart failure. An updated review. Clin. Pharmacokinet.15,94–113 (1988).
  Medline CASGoogle Scholar
• 54  Zordoky BN, El-Kadi AO. Modulation of cardiac and hepatic cytochrome P450 enzymes during heart failure. Curr. Drug Metab.9,122–128 (2008).
  Medline CASGoogle Scholar
• 55  Catananti C, Liperoti R, Settanni S et al. Heart failure and adverse drug reactions among hospitalized older adults. Clin. Pharmacol. Ther.86,307–310 (2009).
  Medline CASGoogle Scholar
• 56  Havranek EP, Ware MG, Lowes BD. Prevalence of depression in congestive heart failure. Am. J. Cardiol.84,348–350, A349 (1999).
  Medline CASGoogle Scholar
• 57  Gottlieb SS, Khatta M, Friedmann E et al. The influence of age, gender, and race on the prevalence of depression in heart failure patients. J. Am. Coll. Cardiol.43,1542–1549 (2004).
  MedlineGoogle Scholar
• 58  Sherwood A, Blumenthal JA, Trivedi R et al. Relationship of depression to death or hospitalization in patients with heart failure. Arch. Intern. Med.167,367–373 (2007).
  MedlineGoogle Scholar
• 59  O’Connor CM, Jiang W, Kuchibhatla M et al. Antidepressant use, depression, and survival in patients with heart failure. Arch. Intern. Med.168,2232–2237 (2008).
  MedlineGoogle Scholar
• 60  Glassman AH, O’Connor CM, Califf RM et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA288,701–709 (2002).
  Medline CASGoogle Scholar
• 61  Tata LJ, West J, Smith C et al. General population based study of the impact of tricyclic and selective serotonin reuptake inhibitor antidepressants on the risk of acute myocardial infarction. Heart91,465–471 (2005).
  Medline CASGoogle Scholar
• 62  The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N. Engl. J. Med.321,406–412 (1989).
  MedlineGoogle Scholar
• 63  Whang W, Kubzansky LD, Kawachi I et al. Depression and risk of sudden cardiac death and coronary heart disease in women: results from the Nurses’ Health Study. J. Am. Coll. Cardiol.53,950–958 (2009).
  MedlineGoogle Scholar
• 64  Smoller JW, Allison M, Cochrane BB et al. Antidepressant use and risk of incident cardiovascular morbidity and mortality among postmenopausal women in the Women’s Health Initiative study. Arch. Intern. Med.169,2128–2139 (2009).
  MedlineGoogle Scholar
• 65  Onder G, Penninx BW, Landi F et al. Depression and adverse drug reactions among hospitalized older adults. Arch. Intern. Med.163,301–305 (2003).
  MedlineGoogle Scholar
• 66  Regitz-Zagrosek V, Petrov G, Lehmkuhl E et al. Heart transplantation in women with dilated cardiomyopathy. Transplantation89,236–244 (2011).
  Google Scholar
• 67  Pina IL, Kokkinos P, Kao A et al. Baseline differences in the HF-ACTION trial by sex. Am. Heart J.158,S16–23 (2009).
  Medline CASGoogle Scholar
• 68  Rathore SS, Foody JM, Wang Y et al. Sex, quality of care, and outcomes of elderly patients hospitalized with heart failure: findings from the National Heart Failure Project. Am. Heart J.149,121–128 (2005).
  MedlineGoogle Scholar
• 69  Taylor DO, Edwards LB, Boucek MM et al. Registry of the International Society for Heart and Lung Transplantation: twenty-third official adult heart transplantation report – 2006. J. Heart Lung Transplant25,869–879 (2006).
  MedlineGoogle Scholar
• 70  Tsai FC, Marelli D, Bresson J et al. Recent trends in early outcome of adult patients after heart transplantation: a single-institution review of 251 transplants using standard donor organs. Am. J. Transplant.2,539–545 (2002).
  MedlineGoogle Scholar
• 71  Kirsch M, Baufreton C, Naftel DC, Benvenuti C, Loisance DY. Pretransplantation risk factors for death after heart transplantation: the Henri Mondor experience. J. Heart Lung Transplant17,268–277 (1998).
  Medline CASGoogle Scholar
• 72  Prendergast TW, Furukawa S, Beyer AJ 3rd, Browne BJ, Eisen HJ, Jeevanandam V. The role of gender in heart transplantation. Ann. Thorac. Surg.65,88–94 (1998).
  Medline CASGoogle Scholar
• 73  Schlechta B, Kocher AA, Ofner P et al. Impact of gender mismatch on the outcome of heart transplantation. Transplant. Proc.31,3340–3342 (1999).
  Medline CASGoogle Scholar
• 74  Welp H, Spieker T, Erren M, Scheld HH, Baba HA, Stypmann J. Sex mismatch in heart transplantation is associated with increased number of severe rejection episodes and shorter long-term survival. Transplant. Proc.41,2579–2584 (2009).
  Medline CASGoogle Scholar
• 75  Zeier M, Dohler B, Opelz G, Ritz E. The effect of donor gender on graft survival. J. Am. Soc. Nephrol.13,2570–2576 (2002).
  MedlineGoogle Scholar
• 76  Herity NA, Lo S, Lee DP et al. Effect of a change in gender on coronary arterial size: a longitudinal intravascular ultrasound study in transplanted hearts. J. Am. Coll. Cardiol.41,1539–1546 (2003).
  MedlineGoogle Scholar
• 77  Kuypers DR. Immunotherapy in elderly transplant recipients: a guide to clinically significant drug interactions. Drugs Aging26,715–737 (2009).
  Medline CASGoogle Scholar
• 78  Morgan ET, Li-Masters T, Cheng PY. Mechanisms of cytochrome P450 regulation by inflammatory mediators. Toxicology181–182,207–210 (2002).
  Medline CASGoogle Scholar
• 79  Kahan BD, Kramer WG, Wideman C, Flechner SM, Lorber MI, Van Buren CT. Demographic factors affecting the pharmacokinetics of cyclosporine estimated by radioimmunoassay. Transplantation41,459–464 (1986).
  Medline CASGoogle Scholar
• 80  Pea F, Pavan F, Furlanut M. Clinical relevance of pharmacokinetics and pharmacodynamics in cardiac critical care patients. Clin. Pharmacokinet.47,449–462 (2008).
  Medline CASGoogle Scholar
• 81  Aroldi A, Tarantino A, Montagnino G, Cesana B, Cocucci C, Ponticelli C. Effects of three immunosuppressive regimens on vertebral bone density in renal transplant recipients: a prospective study. Transplantation63,380–386 (1997).
  Medline CASGoogle Scholar
• 82  Csete M. Gender issues in transplantation. Anesth. Analg.107,232–238 (2008).
  MedlineGoogle Scholar
• 83  Pond GR, Lipton JH, Messner HA. Long-term survival after blood and marrow transplantation: comparison with an age- and gender-matched normative population. Biol. Blood Marrow Transplant.12,422–429 (2006).
  MedlineGoogle Scholar
• 84  Fuge R, Bird JM, Fraser A et al. The clinical features, risk factors and outcome of thrombotic thrombocytopenic purpura occurring after bone marrow transplantation. Br. J. Haematol.113,58–64 (2001).
  Medline CASGoogle Scholar
• 85  Bai Y, Sun T, Ye P. Age, gender and diabetic status are associated with effects of bone marrow cell therapy on recovery of left ventricular function after acute myocardial infarction: a systematic review and meta-analysis. Ageing Res. Rev.9,418–423 (2011).
  Google Scholar
• 86  Edelman AB, Cherala G, Stanczyk FZ. Metabolism and pharmacokinetics of contraceptive steroids in obese women: a review. Contraception82,314–323 (2011).
  Google Scholar
• 87  Rakusan K. Drugs in pregnancy: implications for a cardiologist. Exp. Clin. Cardiol.15,e100–e103 (2011).
  Google Scholar
• 88  Hameed AB, Sklansky MS. Pregnancy: maternal and fetal heart disease. Curr. Probl. Cardiol.32,419–494 (2007).
  MedlineGoogle Scholar
• 89  Anderson GD, Carr DB. Effect of pregnancy on the pharmacokinetics of antihypertensive drugs. Clin. Pharmacokinet.48,159–168 (2009).
  Medline CASGoogle Scholar
• 90  Yoder SR, Thornburg LL, Bisognano JD. Hypertension in pregnancy and women of childbearing age. Am. J. Med.122,890–895 (2009).
  MedlineGoogle Scholar
• 91  Podymow T, August P. Antihypertensive drugs in pregnancy. Semin. Nephrol.31,70–85 (2011).
  Medline CASGoogle Scholar
• 92  Kher A, Bauersachs R, Nielsen JD. The management of thrombosis in pregnancy: role of low-molecular-weight heparin. Thromb. Haemost.97,505–513 (2007).
  Medline CASGoogle Scholar
• 93  Anderson GD. Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach. Clin. Pharmacokinet.44,989–1008 (2005).
  Medline CASGoogle Scholar
• 94  Pavek P, Ceckova M, Staud F. Variation of drug kinetics in pregnancy. Curr. Drug Metab.10,520–529 (2009).
  Medline CASGoogle Scholar
• 95  Ho RH, Kim RB. Transporters and drug therapy: implications for drug disposition and disease. Clin. Pharmacol. Ther.78,260–277 (2005).
  Medline CASGoogle Scholar
• 96  Maeno Y, Hirose A, Kanbe T, Hori D. Fetal arrhythmia: prenatal diagnosis and perinatal management. J. Obstet. Gynaecol. Res.35,623–629 (2009).
  MedlineGoogle Scholar
• 97  Mattison DR. Transdermal drug absorption during pregnancy. Clin. Obstet. Gynecol.33,718–727 (1990).
  Medline CASGoogle Scholar
• 98  Hebert MF, Easterling TR, Kirby B et al. Effects of pregnancy on CYP3A and P-glycoprotein activities as measured by disposition of midazolam and digoxin: a University of Washington specialized center of research study. Clin. Pharmacol. Ther.84,248–253 (2008).
  Medline CASGoogle Scholar
• 99  Davis RL, Eastman D, McPhillips H et al. Risks of congenital malformations and perinatal events among infants exposed to calcium channel and β-blockers during pregnancy. Pharmacoepidemiol. Drug Saf.20,138–145 (2011).
  MedlineGoogle Scholar
• 100  Brancazio LR, Roperti KA, Stierer R, Laifer SA. Pharmacokinetics and pharmacodynamics of subcutaneous heparin during the early third trimester of pregnancy. Am. J. Obstet. Gynecol.173,1240–1245 (1995).
  Medline CASGoogle Scholar
• 101  Blomback M, Bremme K, Hellgren M, Lindberg H. A pharmacokinetic study of dalteparin (Fragmin) during late pregnancy. Blood Coagul. Fibrinolysis9,343–350 (1998).
  Medline CASGoogle Scholar
• 102  Norris LA, Bonnar J, Smith MP, Steer PJ, Savidge G. Low molecular weight heparin (tinzaparin) therapy for moderate risk thromboprophylaxis during pregnancy. A pharmacokinetic study. Thromb. Haemost.92,791–796 (2004).
  Medline CASGoogle Scholar
• 103  Buchanan ML, Easterling TR, Carr DB et al. Clonidine pharmacokinetics in pregnancy. Drug Metab. Dispos.37,702–705 (2009).
  Medline CASGoogle Scholar
• 104  Weinera CP, Buhimschib C, Swaanc P. Drug-prescribing challenges during pregnancy. Curr. Obstet. Gynaecol.15,157–165 (2005).
  Google Scholar
• 105  Hardie C, Bain C, Walters M. Hormone replacement therapy: the risks and benefits of treatment. J. R. Coll. Physicians Edinb.39,324–326 (2009).
  Medline CASGoogle Scholar
• 106  Shufelt CL, Bairey Merz CN. Contraceptive hormone use and cardiovascular disease. J. Am. Coll. Cardiol.53,221–231 (2009).
  Medline CASGoogle Scholar
• 107  Mwinyi J, Cavaco I, Pedersen RS et al. Regulation of CYP2C19 expression by estrogen receptor α: implications for estrogen-dependent inhibition of drug metabolism. Mol. Pharmacol.78,886–894 (2011).
  Google Scholar
• 108  Zingone MM, Guirguis AB, Airee A, Cobb D. Probable drug interaction between warfarin and hormonal contraceptives. Ann. Pharmacother.43,2096–2102 (2009).
  MedlineGoogle Scholar
• 109  Frohlich M, Albermann N, Sauer A, Walter-Sack I, Haefeli WE, Weiss J. In vitro and ex vivo evidence for modulation of P-glycoprotein activity by progestins. Biochem. Pharmacol.68,2409–2416 (2004).
  MedlineGoogle Scholar
• 110  Sims ST, Rehrer NJ, Bell ML, Cotter JD. Endogenous and exogenous female sex hormones and renal electrolyte handling: effects of an acute sodium load on plasma volume at rest. J. Appl. Physiol.105,121–127 (2008).
  Medline CASGoogle Scholar
• 111  Bloemenkamp KW. Epidemiology of oral contraceptive related thrombosis. Thromb. Res.115(Suppl. 1),1–6 (2005).
  MedlineGoogle Scholar
• 112  Olah L, Valikovics A, Bereczki D, Fulesdi B, Munkacsy C, Csiba L. Gender-related differences in acetazolamide-induced cerebral vasodilatory response: a transcranial Doppler study. J. Neuroimaging10,151–156 (2000).
  Medline CASGoogle Scholar
• 113  Bierman AS, Pugh MJ, Dhalla I et al. Sex differences in inappropriate prescribing among elderly veterans. Am. J. Geriatr. Pharmacother.5,147–161 (2007).
  MedlineGoogle Scholar
• 114  Johnell K, Weitoft GR, Fastbom J. Sex differences in inappropriate drug use: a register-based study of over 600,000 older people. Ann. Pharmacother.43,1233–1238 (2009).
  MedlineGoogle Scholar
• 115  Sikdar KC, Alaghehbandan R, MacDonald D et al. Adverse drug events in adult patients leading to emergency department visits. Ann. Pharmacother.44,641–649 (2011).
  Google Scholar
• 116  Rivero A, Curtis AB. Sex differences in arrhythmias. Curr. Opin. Cardiol.25,8–15 (2011).
  Google Scholar
• 117  Jones SG, Momin SR, Good MW, Shea TK, Patric K. Distal upper and lower limb fractures associated with thiazolidinedione use. Am. J. Manag. Care15,491–496 (2009).
  MedlineGoogle Scholar
• 118  Borchers AT, Keen CL, Gershwin ME. Drug-induced lupus. Ann. NY Acad. Sci.1108,166–182 (2007).
  Medline CASGoogle Scholar
• 119  Onder G, Liperoti R, Soldato M, Cipriani MC, Bernabei R, Landi F. Depression and risk of nursing home admission among older adults in home care in Europe: results from the Aged in Home Care (AdHOC) study. J. Clin. Psychiatry68,1392–1398 (2007).
  MedlineGoogle Scholar
• 120  Zender R, Olshansky E. Women’s mental health: depression and anxiety. Nurs. Clin. North Am.44,355–364 (2009).
  MedlineGoogle Scholar
• 121  Barsky AJ, Peekna HM, Borus JF. Somatic symptom reporting in women and men. J. Gen. Intern. Med.16,266–275 (2001).
  Medline CASGoogle Scholar
• 122  Beijer HJ, de Blaey CJ. Hospitalisations caused by adverse drug reactions (ADR): a meta-analysis of observational studies. Pharm. World Sci.24,46–54 (2002).
  Medline CASGoogle Scholar
• 123  Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA279,1200–1205 (1998).
  Medline CASGoogle Scholar
• 124  Rodenburg EM, Stricker BH, Visser LE. Sex-related differences in hospital admissions attributed to adverse drug reactions in the Netherlands. Br. J. Clin. Pharmacol.71,95–104 (2011).
  MedlineGoogle Scholar
• 125  Lansky AJ, Pietras C, Costa RA et al. Gender differences in outcomes after primary angioplasty versus primary stenting with and without abciximab for acute myocardial infarction: results of the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. Circulation111,1611–1618 (2005).
  Medline CASGoogle Scholar
• 126  Hreiche R, Morissette P, Turgeon J. Drug-induced long QT syndrome in women: review of current evidence and remaining gaps. Gend. Med.5,124–135 (2008).
  MedlineGoogle Scholar
• 127  Eckardt L. Gender differences in Brugada syndrome. J. Cardiovasc. Electrophysiol.18,422–424 (2007).
  MedlineGoogle Scholar
• 128  Gaborit N, Varro A, Le Bouter S et al. Gender-related differences in ion-channel and transporter subunit expression in non-diseased human hearts. J. Mol. Cell. Cardiol.49,639–646 (2011).
  Google Scholar
• 129  James AF, Choisy SC, Hancox JC. Recent advances in understanding sex differences in cardiac repolarization. Prog. Biophys. Mol. Biol.94,265–319 (2007).
  MedlineGoogle Scholar
• 130  Kurokawa J, Suzuki T, Furukawa T. New aspects for the treatment of cardiac diseases based on the diversity of functional controls on cardiac muscles: acute effects of female hormones on cardiac ion channels and cardiac repolarization. J. Pharmacol. Sci.109,334–340 (2009).
  Medline CASGoogle Scholar
• 131  Coker SJ. Drugs for men and women – how important is gender as a risk factor for TdP? Pharmacol. Ther.119,186–194 (2008).
  Medline CASGoogle Scholar
• 132  Di Diego JM, Cordeiro JM, Goodrow RJ et al. Ionic and cellular basis for the predominance of the Brugada syndrome phenotype in males. Circulation106,2004–2011 (2002).
  MedlineGoogle Scholar
• 133  Shimizu W, Antzelevitch C, Suyama K et al. Effect of sodium channel blockers on ST segment, QRS duration, and corrected QT interval in patients with Brugada syndrome. J. Cardiovasc. Electrophysiol.11,1320–1329 (2000).
  Medline CASGoogle Scholar
• 134  Cohen M, Alexander KP, Rao SV. Bleeding after anti-thrombotic therapy in patients with acute ischemic heart disease: is it the drugs or how we use them? J. Thromb. Thrombolysis26,175–182 (2008).
  Medline CASGoogle Scholar
• 135  Hallas J, Gram LF, Grodum E et al. Drug related admissions to medical wards: a population based survey. Br. J. Clin. Pharmacol.33,61–68 (1992).
  Medline CASGoogle Scholar
• 136  Zuern CS, Lindemann S, Gawaz M. Platelet function and response to aspirin: gender-specific features and implications for female thrombotic risk and management. Semin. Thromb. Hemost.35,295–306 (2009).
  Medline CASGoogle Scholar
• 137  Toth B, Nikolajek K, Rank A et al. Gender-specific and menstrual cycle dependent differences in circulating microparticles. Platelets18,515–521 (2007).
  Medline CASGoogle Scholar
• 138  Gorton HJ, Warren ER, Simpson NA, Lyons GR, Columb MO. Thromboelastography identifies sex-related differences in coagulation. Anesth. Analg.91,1279–1281 (2000).
  Medline CASGoogle Scholar
• 139  Lowe GD, Rumley A, Woodward M et al. Epidemiology of coagulation factors, inhibitors and activation markers: the Third Glasgow MONICA Survey. I. Illustrative reference ranges by age, sex and hormone use. Br. J. Haematol.97,775–784 (1997).
  Medline CASGoogle Scholar
• 140  Faraday N, Goldschmidt-Clermont PJ, Bray PF. Gender differences in platelet GPIIb-IIIa activation. Thromb. Haemost.77,748–754 (1997).
  Medline CASGoogle Scholar
• 141  Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA295,306–313 (2006).
  Medline CASGoogle Scholar
• 142  Boersma E, Harrington RA, Moliterno DJ et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet359,189–198 (2002).
  Medline CASGoogle Scholar
• 143  Antiplatelet Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ324,71–86 (2002).
  MedlineGoogle Scholar
• 144  Ridker PM, Cook NR, Lee IM et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N. Engl. J. Med.352,1293–1304 (2005).
  Medline CASGoogle Scholar
• 145  Berger JS, Bhatt DL, Cannon CP et al. The relative efficacy and safety of clopidogrel in women and men a sex-specific collaborative meta-analysis. J. Am. Coll. Cardiol.54,1935–1945 (2009).
  Medline CASGoogle Scholar
• 146  Cho L, Topol EJ, Balog C et al. Clinical benefit of glycoprotein IIb/IIIa blockade with Abciximab is independent of gender: pooled analysis from EPIC, EPILOG and EPISTENT trials. Evaluation of 7E3 for the prevention of ischemic complications. Evaluation in percutaneous transluminal coronary angioplasty to improve long-term outcome with abciximab GP IIb/IIIa BLOCKADE. Evaluation of platelet IIb/IIIa inhibitor for stent. J. Am. Coll. Cardiol.36,381–386 (2000).
  Medline CASGoogle Scholar
• 147  Fernandes LS, Tcheng JE, O’Shea JC et al. Is glycoprotein IIb/IIIa antagonism as effective in women as in men following percutaneous coronary intervention? Lessons from the ESPRIT study. J. Am. Coll. Cardiol.40,1085–1091 (2002).
  MedlineGoogle Scholar
• 148  The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. Platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy. N. Engl. J. Med.339,436–443 (1998).
  MedlineGoogle Scholar
• 149  Lincoff AM, Harrington RA, Califf RM et al. Management of patients with acute coronary syndromes in the United States by platelet glycoprotein IIb/IIIa inhibition. Insights from the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial. Circulation102,1093–1100 (2000).
  Medline CASGoogle Scholar
• 150  Huynh T, Theroux P, Snapinn S, Wan Y. Effect of platelet glycoprotein IIb/IIIa receptor blockade with tirofiban on adverse cardiac events in women with unstable angina/non-ST-elevation myocardial infarction (PRISM-PLUS Study). Am. Heart J.146,668–673 (2003).
  Medline CASGoogle Scholar
• 151  Poli D, Antonucci E, Grifoni E, Abbate R, Gensini GF, Prisco D. Gender differences in stroke risk of atrial fibrillation patients on oral anticoagulant treatment. Thromb. Haemost.101,938–942 (2009).
  Medline CASGoogle Scholar
• 152  Alexander KP, Chen AY, Newby LK et al. Sex differences in major bleeding with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE (can rapid risk stratification of unstable angina patients suppress adverse outcomes with early implementation of the ACC/AHA guidelines) initiative. Circulation114,1380–1387 (2006).
  Medline CASGoogle Scholar
• 153  McRae S, Tran H, Schulman S, Ginsberg J, Kearon C. Effect of patient’s sex on risk of recurrent venous thrombo-embolism: a meta-analysis. Lancet368,371–378 (2006).
  MedlineGoogle Scholar
• 154  Mazziotti G, Canalis E, Giustina A. Drug-induced osteoporosis: mechanisms and clinical implications. Am. J. Med.123,877–884 (2011).
  Google Scholar
• 155  Rejnmark L, Vestergaard P, Mosekilde L. Fracture risk in users of oral anticoagulants: a nationwide case-control study. Int. J. Cardiol.118,338–344 (2007).
  MedlineGoogle Scholar
• 156  Duhl AJ, Paidas MJ, Ural SH et al. Anti-thrombotic therapy and pregnancy: consensus report and recommendations for prevention and treatment of venous thrombo-embolism and adverse pregnancy outcomes. Am. J. Obstet. Gynecol.197,457 e451–e421 (2007).
  MedlineGoogle Scholar
• 157  Levin A, Ben-Artzi M, Beckerman P et al. Factors associated with bleeding in elderly hospitalized patients treated with enoxaparin sodium : a prospective, open-label, observational study. Drugs Aging26,77–85 (2009).
  Medline CASGoogle Scholar
• 158  Campbell NR, Hull RD, Brant R, Hogan DB, Pineo GF, Raskob GE. Different effects of heparin in males and females. Clin. Invest. Med.21,71–78 (1998).
  Medline CASGoogle Scholar
• 159  Oldgren J, Johnston N, Siegbahn A. Xa inhibition and coagulation activity – the influence of prolonged dalteparin treatment and gender in patients with acute coronary syndrome and healthy individuals. Am. Heart J.155,493 e491–e498 (2008).
  MedlineGoogle Scholar
• 160  Warkentin TE, Sheppard JA, Sigouin CS, Kohlmann T, Eichler P, Greinacher A. Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia. Blood108,2937–2941 (2006).
  Medline CASGoogle Scholar
• 161  Schindewolf M, Schwaner S, Wolter M et al. Incidence and causes of heparin-induced skin lesions. CMAJ181,477–481 (2009).
  MedlineGoogle Scholar
• 162  Reed MD, Bell D. Clinical pharmacology of bivalirudin. Pharmacotherapy22,105S–111S (2002).
  Medline CASGoogle Scholar
• 163  Lansky AJ, Mehran R, Cristea E et al. Impact of gender and antithrombin strategy on early and late clinical outcomes in patients with non-ST-elevation acute coronary syndromes (from the ACUITY trial). Am. J. Cardiol.103,1196–1203 (2009).
  MedlineGoogle Scholar
• 164  Swan SK, Hursting MJ. The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy20,318–329 (2000).
  Medline CASGoogle Scholar
• 165  Stangier J, Stahle H, Rathgen K, Fuhr R. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin. Pharmacokinet.47,47–59 (2008).
  Medline CASGoogle Scholar
• 166  Peterson ED, Lansky AJ, Kramer J, Anstrom K, Lanzilotta MJ. Effect of gender on the outcomes of contemporary percutaneous coronary intervention. Am. J. Cardiol.88,359–364 (2001).
  Medline CASGoogle Scholar
• 167  Malenka DJ, Wennberg DE, Quinton HA et al. Gender-related changes in the practice and outcomes of percutaneous coronary interventions in northern New England from 1994 to 1999. J. Am. Coll. Cardiol.40,2092–2101 (2002).
  MedlineGoogle Scholar
• 168  Soumerai SB, McLaughlin TJ, Ross-Degnan D, Christiansen CL, Gurwitz JH. Effectiveness of thrombolytic therapy for acute myocardial infarction in the elderly: cause for concern in the old-old. Arch. Intern. Med.162,561–568 (2002).
  MedlineGoogle Scholar
• 169  Angeja BG, Rundle AC, Gurwitz JH, Gore JM, Barron HV. Death or nonfatal stroke in patients with acute myocardial infarction treated with tissue plasminogen activator. Participants in the National Registry of Myocardial Infarction 2. Am. J. Cardiol.87,627–630, A629 (2001).
  Medline CASGoogle Scholar
• 170  MacMahon S, Peto R, Cutler J et al. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet335,765–774 (1990).
  Medline CASGoogle Scholar
• 171  Sutton-Tyrrell K, Wildman R, Newman A, Kuller LH. Extent of cardiovascular risk reduction associated with treatment of isolated systolic hypertension. Arch. Intern. Med.163,2728–2731 (2003).
  MedlineGoogle Scholar
• 172  Thoenes M, Neuberger HR, Volpe M, Khan BV, Kirch W, Bohm M. Antihypertensive drug therapy and blood pressure control in men and women: an international perspective. J. Hum. Hypertens.24,336–344 (2011).
  Google Scholar
• 173  Hwang KS, Kim GH. Thiazide-induced hyponatremia. Electrolyte Blood Press.8,51–57 (2011).▪▪ Discusses thiazide-induced hyponatremia and its possible pathophysiological mechanisms.
  Google Scholar
• 174  Chow KM, Szeto CC, Wong TY, Leung CB, Li PK. Risk factors for thiazide-induced hyponatremia. QJM96,911–917 (2003).
  Medline CASGoogle Scholar
• 175  Sharabi Y, Illan R, Kamari Y et al. Diuretic induced hyponatremia in elderly hypertensive women. J. Hum. Hypertens.16,631–635 (2002).
  Medline CASGoogle Scholar
• 176  Grikiniene J, Volbekas V, Stakisaitis D. Gender differences of sodium metabolism and hyponatremia as an adverse drug effect. Medicina (Kaunas)40,935–942 (2004).
  MedlineGoogle Scholar
• 177  Kjeldsen K. Hypokalemia and sudden cardiac death. Exp. Clin. Cardiol.15,e96–e99 (2011).
  Google Scholar
• 178  Rahman AR, McDevitt DG, Struthers AD, Lipworth BJ. Sex differences in hypokalaemic and electrocardiographic effects of inhaled terbutaline. Thorax47,1056–1059 (1992).
  Medline CASGoogle Scholar
• 201  Indiana University School of Medicine. Drug interactions: cytochrome P450 drug interaction table. http://medicine.iupui.edu/flockhart/table.htm
  Google Scholar
• 202  American Heart Association. Heart transplants: statistics 2009. http://americanHeartorg/presenter.jhtml?identifier=4588
  Google Scholar
• 203  WHO. Medical eligibility criteria for contraceptive use. www.who.int/reproductivehealth/publications/family_planning/9789241563888/en/index.html
  Google Scholar
• 204  Faculty of Sexual and Reproductive Health Care. UK medical eligibility criteria for contraceptive use. www.fsrh.org/admin/uploads/UKMEC2009.pdf
  Google Scholar